Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03267563 · ClinicalTrials.gov registry record · NA

Minimum Intervention to Maintain a Postpartum Depression Prevention Program in Clinics Serving Low-income Women

A NA study, sponsored by Michigan State University.

Completed
Registry status
NA
Development phase
160
Enrollment target

NCT03267563: Completed NA study, sponsored by Michigan State University.

NCT03267563 is a NA study that has completed, run by Michigan State University. The registered enrollment target is 160 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03267563, a NA study, has completed, sponsored by Michigan State University.

COMPLETED
Registry status
NA
Development phase
160 participants
Enrollment target

Study Summary

Postpartum depression (PPD) is common and can have lasting consequences for mother and child. ROSE is an intervention to prevent PPD, delivered during pregnancy in outpatient prenatal settings. ROSE has been found to significantly reduce cases of PPD in multiple randomized trials in community prenatal settings with racially and ethnically diverse low-income pregnant women. Requests for ROSE training and recent policy changes supporting payment for comprehensive perinatal services to underserved populations suggest a context ripe for embedding ROSE in prenatal clinics long-term. Given the need for return on investment studies about sustainment efforts, we propose a Sequential Multiple Assignment Randomized (SMART) Trial of the effectiveness and cost-effectiveness of a stepwise approach to sustainment of ROSE in 90 outpatient clinics providing prenatal care to pregnant women on public assistance in 6 U.S. states. In Year 1, all clinics will receive enhanced implementation as usual (EIAU; initial training + tools for sustainment). At the first time at which a clinic is determined to be at risk for failure to sustain (i.e., at 3, 6, 9, 12, 15 months), that clinic will be randomized to receive either: (1) no additional implementation support (i.e., EIAU only), or (2) low-intensity coaching and feedback (LICF). If clinics receiving LICF are still found to be at risk at subsequent assessments, they will be randomized to either (1) EIAU + LICF only, or (2) high-intensity coaching and feedback (HICF). Additional study follow-up interviews will occur at 18, 24, and 30 months, but no implementation intervention will occur after 18 months. Outcomes include: 1. Sustainment of core program elements at each time point and total length of time ROSE services were provided and were provided with at least moderate fidelity. 2. Health impact (PPD rates over time at each clinic) and reach. 3. ROI (costs, cost-offsets, and cost-effectiveness) of each sustainment step. Hypothesized mechan

Primary Outcome

Proportion sustainment of ROSE's core program elements, assessed using the ROSE Session-by-Session Adherence Scale, was defined as the mean proportion of core elements delivered that should have been delivered at each ROSE session over the time period (zero if no sessions were completed). Potential range is 0 to 1, higher score reflects better outcome.

Interventions

  • BEHAVIORAL EIAU
  • BEHAVIORAL LICF
  • BEHAVIORAL HICF

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2018-06-12
Est. Completion 2023-12-31
Phase NA
Michigan State University

120 total trials

What the finished NCT03267563 record still lists

NCT03267563 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 3 interventions - of which EIAU is the first listed.

NCT03267563 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03267563 about?

NCT03267563 is a clinical study titled "Minimum Intervention to Maintain a Postpartum Depression Prevention Program in Clinics Serving Low-income Women". Postpartum depression (PPD) is common and can have lasting consequences for mother and child. ROSE is an intervention to prevent PPD, delivered during pregnancy in outpatient prenatal settings. ROSE has been found to significantly reduce cases of PPD in multiple randomized trials in community prenat...

What is the current status of trial NCT03267563?

This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2018-06-12. Estimated completion is 2023-12-31.

What interventions are being tested in trial NCT03267563?

The interventions under investigation include: EIAU (BEHAVIORAL), LICF (BEHAVIORAL), HICF (BEHAVIORAL).

Who is sponsoring clinical trial NCT03267563?

This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03267563's enrollment target sits among peer trials

160 628th of 2000 higher than 1,347 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03267563, the US trial registry maintained by the National Library of Medicine. NCT03267563 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.